HIGHLIGHTS: Emma Walmsley - CEO of GSK
Listen to the original audio · Transcribed with NVIDIA Parakeet · Why times can differ in your player
Mm. Hi everybody, tune in to this short version of the podcast, which we do every Friday, for the long version. Tune in on Wednesdays. Hi, everyone, I'm Nikola Tanyan, the CEO of the Norwegian Sovereign Wealth Fund. And today I'm in really good company with Emma Walmsley, the CEO of GSK. One of the global leaders in pharmaceuticals.
Now We own one point seven percent of GSK valued at one point three billion US dollars. Emma, great to have you here. Wonderful to be here. Thanks for having me. And I believe this is the second podcast ever in your life. Second ever. Wow. Looking forward uh very much to the conversation. Now which areas of research excites you the most just now.
What excites me most is when we can innovate in a way that has real impact at scale for patients around the world. So I'm incredibly excited about five new approvals for new drugs and vaccines that we're expecting to get this year, one down and another four to go. And that's the first wave of a cohort of, we think, 14 scale medicines and vaccines, each with a potential of more than two billion pounds worth of sales that we expect to launch this decade. And that includes uh in in areas of oncology, in infectious diseases, in respiratory immunology, in HIV. And You know
We already have this episode, so unlocking it is cheap and permanent: the full transcript (11 minutes, 1,727 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.
No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 5 episodes for $3.49, and monthly plans are cheaper still.